Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options |
| |
| Authors: | Cristian St&#x;tescu &#x;tefana Enachi Carina Ureche Laura
&#x;poi Larisa Anghel Delia &#x;alaru Carmen Ple&#x;oianu M&#x;d&#x;lina Bostan Drago&#x; Marcu Mircea Ovanez Balasanian Radu Andy Sasc&#x;u |
| |
| Affiliation: | 1.Cardiology Department, Cardiovascular Diseases Institute “Prof. Dr. George I.M. Georgescu”, Carol I Boulevard No. 50, 700503 Iași, Romania; (C.S.); (C.U.); (L.Ț.); (L.A.); (D.Ș.); (C.P.); (M.B.); (D.M.); (M.O.B.); (R.A.S.);2.Internal Medicine Department, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania |
| |
| Abstract: | Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiac disease with a highly variable phenotypic expression, ranging from asymptomatic to drug refractory heart failure (HF) presentation. Pharmacological therapy is the first line of treatment, but options are currently limited to nonspecific medication like betablockers or calcium channel inhibitors, with frequent suboptimal results. While being the gold standard practice for the management of drug refractory HCM patients, septal reduction therapy (SRT) remains an invasive procedure with associated surgical risks and it requires the expertise of the operating centre, thus limiting its accessibility. It is therefore with high interest that researchers look for pharmacological alternatives that could provide higher rates of success. With new data gathering these past years as well as the development of a new drug class showing promising results, this review provides an up-to-date focused synthesis of existing medical treatment options and future directions for HCM pharmacological treatment. |
| |
| Keywords: | hypertrophic cardiomyopathy pharmacotherapy drug trials myosin inhibitors mavacamten |
|
|
